Intravenous ferric derisomaltose for the treatment of iron deficiency anemia
Michael Auerbach, David H. Henry, Thomas G. DeLoughery
Abstract
Intravenous (IV) iron is the therapy of choice when oral iron is ineffective or poorly tolerated, yet use has been limited by fears of hypersensitivity reactions (HSRs). Newer formulations that bind iron more tightly and release it more slowly have made the risk of serious or severe HSRs very low. One such formulation, ferric derisomaltose, has been approved in the United States for delivery of 1000 mg iron in a single IV infusion. Ferric derisomaltose rapidly repletes iron parameters with low rates of serious or severe HSRs. Single-infusion iron repletion offers convenience, eliminates adherence concerns, and reduces healthcare resource utilization.
Topics & Concepts
Intravenous ironMedicineFerricAnemiaFERRIC IRONIron deficiencyIron-deficiency anemiaIntensive care medicineInternal medicineChemistryFerrousOrganic chemistryIron Metabolism and DisordersErythropoietin and Anemia TreatmentHemoglobinopathies and Related Disorders